Earlier this year, MRC Unit, The Gambia was awarded a major grant by the Bill & Melinda Gates Foundation to undertake a clinical trial of inactivated poliovirus vaccine (IPV) when given concomitantly with other vaccines within the WHO EPI vaccine schedule (measles and rubella combined vaccine and yellow fever vaccine). (more…)
Established in The Gambia in 1947, the MRC is the UK's single largest investment in medical research in a developing country. The Unit's research focuses on infectious diseases of immediate concern to The Gambia and the continent of Africa, with the aim of reducing the burden of illness and death in the country and the developing world as a whole. read more
The scientific evidence supporting the value of vaccination is overwhelming: In terms of reducing the burdenLearn more
In recent times, several diseases have reduced very markedly in incidence in The GambiaLearn more
In common with most developing countries, The Gambia has high infant and child mortality ratesLearn more
The MRC research programme in The Gambia is in the process of reorganization into three new, interlinking, scientific themes: Child Survival, Disease Eradication and Vaccinology.
Emeritus Scientist Professor Hilton Whittle has been studying some of the leading causes of illness and death in the developing world for almost forty years. Hilton, a pioneer of the Gambia Hepatitis Intervention Scheme (GHIS), gives a potted history of one of the longest running longitudinal studies of an infectious disease in the Tropics.
- Host iron redistribution as a risk factor for incident tuberculosis in HIV infection: an 11-year retrospective cohort study.
- PfHPRT: a new biomarker candidate of acute Plasmodium falciparum infection.
- Population dynamics of HIV-2 in rural West Africa: comparison with HIV-1 and ongoing transmission at the heart of the epidemic.
PO Box 273, Banjul
T: +220 4495442/6 or 4494072/9
F: Administration +220 4495919